New findings may lead to relapse-free treatment for a sizeable subgroup of lung cancer patients. In a study in mice, scientists have identified a biomarker that may help physicians select lung cancer patients who can be treated with a single antibody-based drug that is likely to bring about full remission, without cancer relapse.
Study may bring improved therapy to preselected lung cancer patients
